Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT04960956 Terminated - Prostate Cancer Clinical Trials

Glycosylation of Exosomes in Prostate and Urothelial Carcinoma

Start date: October 13, 2016
Phase:
Study type: Observational

The purpose of this study is to collect a urine sample from patients with prostate and urothelial (bladder) cancer and healthy volunteers who do not have cancer, so that researchers can perform studies on microcellular structures called exosomes that may eventually lead to a new type of urinary biomarker test for prostate and urothelial cancer.

NCT ID: NCT04727710 Terminated - Prostate Cancer Clinical Trials

Testing the Effect of Mindfulness for Prostatectomy Outcomes

TEMPO
Start date: August 26, 2020
Phase: N/A
Study type: Interventional

This research project has 2 parts: The first part of the research is to develop a couples-based group mindfulness intervention for men undergoing prostatectomy, with input from patients and their partners. The second part is the trial registered here, which will pilot the researchers' mindfulness intervention, developed in part 1, and observe any reduction of distress for men undergoing prostatectomy and their partners.

NCT ID: NCT04541225 Terminated - Breast Cancer Clinical Trials

Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

Start date: December 8, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

NUV-422-02 is a first-in-human, open-label, Phase 1/2 dose escalation and multiple expansion cohort study designed to evaluate the safety and efficacy of NUV-422. The study population is comprised of adults with recurrent or refractory high-grade gliomas (HGGs), metastatic breast cancer (mBC), with and without brain metastases, and recurrent or refractory metastatic castration-resistant prostate cancer (mCRPC). All patients will self-administer NUV-422 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.

NCT ID: NCT04535908 Terminated - Prostate Cancer Clinical Trials

Hypofractionated Radiotherapy in Prostate Cancer Patients Aged 75 Years or Older.

Start date: September 16, 2020
Phase: N/A
Study type: Interventional

The majority of all new prostate cancer cases are diagnosed in men aged > 70 years, with the highest incidence in men aged > 90 years. Management options for localized prostate cancer include active surveillance in patients with low-risk disease, radical prostatectomy or external beam radiation therapy. In previous studies, hypofractionated prostate cancer irradiation regimens have been shown to represent a highly effective treatment option for prostate cancer. However, patients aged 75 years or older were underrepresented in most trials resulting in the lack of a robust evidence base. The proposed study will evaluate radiation-induced toxicity as well as outcome after hypofractionated external beam radiotherapy in prostate cancer patients aged 75 years or older.

NCT ID: NCT04393831 Terminated - Prostate Cancer Clinical Trials

A Prospective Trial on Nerve Sparing Techniques Performed in Radical Prostatectomy

Start date: June 15, 2021
Phase: N/A
Study type: Interventional

The investigators propose a prospective study to assess recovery of urinary and sexual function by nerve sparing techniques after radical prostatectomy.

NCT ID: NCT04357717 Terminated - Prostate Cancer Clinical Trials

ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting

Start date: March 15, 2020
Phase:
Study type: Observational

The study is designed to confirm the performance of the ExoDx Prostate test in prior negative biopsy patients now presenting for a repeat prostate biopsy. Note: ExoDx Prostate test results are collected for correlation to biopsy results and are not disclosed to the physician or study subject.

NCT ID: NCT04305379 Terminated - Prostate Cancer Clinical Trials

Augmented BLAdder NecK rEconstruction Trial for Improved Urinary Function After Radical Prostatectomy

BLANKET
Start date: January 16, 2020
Phase: N/A
Study type: Interventional

The investigators are conducting a prospective, randomized trial to investigate whether patients randomized to receive an augmented bladder neck reconstruction (aBNR) at the time of robotic-assisted laparoscopic prostatectomy experience improved urinary function post-operatively compared to patients who undergo prostatectomy with a standard BNR. An aBNR here consists of the autologous medial umbilical ligament sling as well as a bladder neck intussusception stitch. The standard BNR group will receive the intussusception stitch only.

NCT ID: NCT04266262 Terminated - Prostate Cancer Clinical Trials

High-Intensity Training for Men With Prostate Cancer on Active Surveillance: A Feasibility Study

Start date: July 9, 2018
Phase: N/A
Study type: Interventional

This is a randomized study aiming to assess the feasibility of a phase II randomized controlled trial of different high-intensity training interventions and usual care (UC) in men with prostate cancer (PCa) undergoing active surveillance (AS).

NCT ID: NCT04221828 Terminated - Prostate Cancer Clinical Trials

Trial of NanoPac Focal Therapy for Prostate Cancer

Start date: October 20, 2020
Phase: Phase 2
Study type: Interventional

This study evaluates the use of NanoPac injected directly into the prostate lesion in men with prostate cancer.

NCT ID: NCT03964337 Terminated - Prostate Cancer Clinical Trials

Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer

SPARC
Start date: March 17, 2020
Phase: Phase 2
Study type: Interventional

This is a prospective, randomized, open-label, phase II trial of cabozantinib in subjects with untreated, high risk prostate cancer undergoing radical prostatectomy. This multicenter study will enroll 30 subjects. Duke is the lead site for this trial. There will be a second site selected TBD. Patients will be assigned (first 9 subjects only) or randomized 2:1 to either: (1) cabozantinib 40 mg by mouth daily for 4 weeks, followed by a 2 week drug washout period before prostatectomy (n = 20), or (2) immediate prostatectomy within 12 weeks of registration (n = 10). The first 9 subjects (6 subjects assigned to cabozantinib treatment, 3 subjects assigned to immediate prostatectomy) will constitute the Safety Lead-In Cohort, which will be only accrued at Duke. After six subjects have received cabozantinib and completed the 57-85 day safety visit without triggering a stopping rule, subjects may be accrued at the ex-Duke site. The primary goal is to compare pathologic apoptotic indices (cleaved caspase-3) in prostatectomy specimens from patients who undergo immediate prostatectomy (controls) versus those who receive with cabozantinib followed by prostatectomy. The secondary objective is to conduct immune phenotypic profiling on the peripheral blood and tumor microenvironment in prostatectomy specimens from both groups. A statistical analysis will be used to compare the apoptotic indices between the two groups.